Singapore-based Alternative Bio Inc. has announced the completion of a seed financing round at USD 15 million, co-led by Eight Roads Ventures with F-Prime Capital and Sequoia China Seed Fund. The proceeds will be used to leverage an innovative discovery platform and advance the company’s lead drug candidates to treat some of the most intractable cancers.
Company Overview and Focus
Alternative Bio is a biotech company developing novel therapeutics targeting post-translational modifying enzymes, with a specialization in signaling, gene expression regulation, cancer biology, and drug discovery. The company aims to address significant unmet medical needs in oncology through its innovative approach.
Scientific Co-Founders
The scientific co-founders of Alternative Bio are Fei Lan, Ph.D., Professor and Vice Dean of the Institute of Biomedical Sciences at Fudan University; Yang Shi, Ph.D., Professor of Epigenetics at Oxford University and the Ludwig Cancer Research Institute, and member of the American Academy of Arts and Sciences and the National Academy of Medicine; and Or Gozani, M.D., Ph.D., the Morris Herzstein Professor of Biology at Stanford University. Their combined expertise in epigenetics, cancer biology, and drug discovery positions Alternative Bio to make significant strides in developing effective treatments for challenging cancers.-Fineline Info & Tech
